The company's main product candidate, vonoprazan, is a new type of medicine that blocks acid secretion in the stomach and has shown promising results in treating gastroesophageal reflux disease and Helicobacter pylori infection. Phathom Pharmaceuticals was launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, and has assembled a team of experienced experts in the gastrointestinal and pharmaceutical industries.